• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc. (Amendment)

    2/14/24 4:02:17 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMVP alert in real time by email
    SC 13G/A 1 ff3027171_13ga3-pmv.htm




    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*


    PMV Pharmaceuticals, Inc.
    (Name of Issuer)
    Common Stock, $0.00001 par value per share
    (Title of Class of Securities)
    69353Y103
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
    ____________
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No.: 69353Y103
    13G
     Page 2 of 9 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    OO
     
     
     
     




    CUSIP No.: 69353Y103
    13G
     Page 3 of 9 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Asset Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    CO
     
     
     
     




    CUSIP No.: 69353Y103
    13G
     Page 4 of 9 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     



    CUSIP No.: 69353Y103
    13G
     Page 5 of 9 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
     
    MVA Investors, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    CO
     
     
     
     




    CUSIP No.: 69353Y103
    13G
     Page 6 of 9 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IN
     
     
     
     



    CUSIP No.: 69353Y103
    13G
     Page 7 of 9 Pages

    This Amendment No. 3 (“Amendment No. 3”) amends and supplements the statement on Schedule 13G filed on September 30, 2020 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), Joe Lewis, MVA Investors, LLC (“MVA Investors”) and Aaron I. Davis (together with Boxer Capital, Boxer Management, Joe Lewis and MVA Investors, the “Reporting Persons”), as amended by Amendment No. 1 on February 14, 2022 and Amendment No. 2 on February 14, 2023 by the Reporting Persons. The Original Filing remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 3. Capitalized terms used and not defined in this Amendment No. 3 have the meanings set forth in the Original Filing, as amended.
    Item 4
    Ownership:

    (a)
    Amount beneficially owned: Boxer, Boxer Management and Joe Lewis beneficially own 0 shares of Common Stock. MVA Investors and Aaron I. Davis beneficially own 0 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 0 shares of Common Stock.

    (b)
    Percent of class: The shares of Common Stock beneficially owned by Boxer Capital, Boxer Management and Joe Lewis represents 0% of the Issuer's outstanding shares of Common Stock. The shares of Common Stock beneficially owned by MVA Investors and Aaron I. Davis represents 0% of the Issuer's outstanding shares of Common Stock. The shares of Common Stock beneficially owned by the Reporting Persons represents, in the aggregate, 0% of the Issuer's outstanding shares of Common Stock.

    (c)
    Number of shares as to which such person has:

    (i)
    sole power to vote or to direct the vote: None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.
    (ii)
    shared power to vote or to direct the vote: Boxer Capital, Boxer Management and Joe Lewis have shared power to vote or to direct the vote of the 0 shares of Common Stock they beneficially own. MVA Investors and Aaron I. Davis have shared power to vote or to direct the vote of the 0 shares of Common Stock they beneficially own.
    (iii)
    sole power to dispose or to direct the disposition of: None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.
    (iv)
    shared power to dispose or to direct the disposition of: Boxer Capital, Boxer Management and Joe Lewis have shared power to dispose or to direct the disposition of the 0 shares of Common Stock they beneficially own. MVA Investors and Aaron I. Davis have shared power to dispose or to direct the disposition of the 0 shares of Common Stock they beneficially own.
    Item 5
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 10
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in





    CUSIP No.: 69353Y103
    13G
     Page 8 of 9 Pages




    connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    Exhibits
    1
    Joint Filing Agreement, dated September 30, 2020, among the Reporting Persons, incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on September 30, 2020.



    CUSIP No.: 69353Y103
    13G
     Page 9 of 9 Pages

    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     Date:  February 14, 2024
     

     
    BOXER CAPITAL, LLC
     
           
     
    By:
      /s/ Aaron I. Davis  
     
    Name:
    Aaron I. Davis
     
     
    Title:
    Authorized Signatory
     
             
     
    BOXER ASSET MANAGEMENT INC.
     
         
     
    By:
      /s/ Paul Higgs  
     
    Name:
    Paul Higgs
     
     
    Title:
    Director
     
             
     
    JOSEPH C. LEWIS
     
         
     
    /s/ Joseph C. Lewis  
     
    Joseph C. Lewis Individually
     
             
     
    MVA INVESTORS, LLC
     
             
     
    By:
       /s/ Aaron I. Davis  
     
    Name:
    Aaron I. Davis
     
     
    Title:
    Authorized Signatory
     
           
     
    AARON I. DAVIS
     
             
       /s/ Aaron I. Davis  
     
    Aaron I. Davis, Individually
     


    Get the next $PMVP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMVP

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Perform → Outperform
    Oppenheimer
    5/13/2024$6.00Buy
    Craig Hallum
    4/12/2024$5.00Buy
    Jefferies
    12/27/2023$7.00Buy
    Ladenburg Thalmann
    3/2/2022$30.00Perform → Outperform
    Oppenheimer
    3/2/2022Perform → Outperform
    Oppenheimer
    9/22/2021$35.00 → $43.00Neutral → Buy
    Goldman Sachs
    8/19/2021Perform
    Oppenheimer
    More analyst ratings

    $PMVP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PMV Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

    11/8/24 7:58:24 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on PMV Pharmaceuticals with a new price target

    Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    5/13/24 8:31:58 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on PMV Pharmaceuticals with a new price target

    Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    4/12/24 7:35:19 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

    Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a median duration of response of 8.0 monthsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 PRINCETON, N.J., Oct.

    10/24/25 11:39:49 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that two abstracts have been accepted for oral and poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 202

    10/13/25 4:01:00 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

    PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027Company to host investor webinar at 8:00 AM ET today to review Phase 2 interim clinical data PRINCETON

    9/10/25 7:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by PMV Pharmaceuticals Inc.

    SCHEDULE 13D/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    10/27/25 5:12:13 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by PMV Pharmaceuticals Inc.

    144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    10/23/25 6:39:20 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by PMV Pharmaceuticals Inc.

    SCHEDULE 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    9/23/25 8:34:40 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mack David Henry exercised 220,643 shares at a strike of $1.37, increasing direct ownership by 96% to 451,109 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    10/29/25 4:11:57 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Orbimed Advisors Llc sold $1,520,000 worth of shares (1,000,000 units at $1.52) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    10/27/25 5:19:23 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Orbimed Advisors Llc sold $900,000 worth of shares (500,000 units at $1.80) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    9/12/25 5:09:08 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Leadership Updates

    Live Leadership Updates

    View All

    PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

    CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in

    11/4/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

    Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr

    3/1/22 7:15:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharma Announces Changes to its Board of Directors

    CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV's Board. "Peter has been an invaluable member of the Board during a period of substantial growth and key successes, including completion of our IPO as well as entry of our lead candidate, PC14586, into the clinic," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "On behalf o

    1/6/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    11/14/24 12:24:48 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    7/8/24 4:32:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care